What EU Expansion Means for the Pharma Industry
Executive Summary
The impact on the pharmaceutical industry of EU expansion in 2004 remains unclear. It may be an opportunity to drive growth in Europe to levels that could potentially rival the US, or it could result in increases to parallel trade, further lowering competitiveness and drug prices in Europe. IMS consultant Janice Haigh assesses the likelihood of both potential outcomes.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?